On 26 November 2025, Boan Biotech announced that Boyoujing® (BA9101), biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), was approved by China’s National Medical Products Administration (NMPA) for the treatment of nAMD and DME (in IV form). The approval follows acceptance (for evaluation) of Boan’s application for the aflibercept biosimilar in July 2024.
According to Boan’s announcement, Boyoujing® will be commercialised in the Chinese mainland by Ocumension, a China-based ophthalmic pharmaceutical platform company, under an agreement entered in 2020.
Qilu Pharmaceutical’s QL1207 was reportedly the first aflibercept biosimilar developed in China, although it is not clear whether it has received formal marketing approval to date.
Aflibercept biosimilars have also been approved and/or launched elsewhere around the world. For example, aflibercept biosimilars currently approved in Europe include Biocon’s Yesafili® (September 2023), Samsung Bioepis/Biogen’s Opuviz™ (SB15) (November 2024), Formycon/Klinge’s Baiama® and Ahzantive® (January 2025), Celltrion’s Eydenzelt® (February 2025), Amgen’s Pavblu® (April 2025), Alvotech/Advanz’s Mynzepli® (August 2025) and Alteogen’s Eyluxvi® (September 2025). Only Sandoz’s Afqlir® has launched in Europe to date (November 2025).
In the US, only a single biosimilar competitor to Regeneron’s Eylea® (aflibercept) is currently on the market (Amgen’s Pavblu®, launched October 2024). However, there are a number of approved aflibercept biosimilars, some of which have scheduled 2026 launch dates as a result of litigation settlements: Biocon’s Yesafili® (due to launch H2/2026), Formycon/Klinge’s Ahzantive® (due to launch Q4/2026), Sandoz’s Enzeevu® (due to launch Q4/2026), Celltrion’s Eydenzelt® (due to launch Q4/2026) and Samsung Bioepis’ Opuviz® (currently subject to pending BPCIA litigation and a preliminary injunction).